Legend Biotech (NASDAQ:LEGN) PT Lowered to $73.00 at HC Wainwright

Legend Biotech (NASDAQ:LEGN) had its price objective cut by HC Wainwright from $86.00 to $73.00 in a report released on Friday, Marketbeat Ratings reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Legend Biotech’s Q4 2025 earnings at $0.10 EPS.

Several other brokerages have also issued reports on LEGN. Cantor Fitzgerald began coverage on Legend Biotech in a research note on Wednesday, April 3rd. They set an overweight rating and a $82.00 price target on the stock. Deutsche Bank Aktiengesellschaft started coverage on Legend Biotech in a research note on Thursday. They issued a buy rating and a $60.00 target price for the company. Raymond James initiated coverage on shares of Legend Biotech in a research note on Wednesday, March 13th. They set an outperform rating and a $86.00 price target on the stock. Scotiabank upgraded shares of Legend Biotech from a sector perform rating to a sector outperform rating and set a $65.00 price objective for the company in a research note on Wednesday, April 17th. Finally, Royal Bank of Canada lifted their target price on shares of Legend Biotech from $85.00 to $86.00 and gave the company an outperform rating in a research report on Tuesday, May 14th. Eleven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Legend Biotech presently has a consensus rating of Buy and a consensus price target of $81.10.

Legend Biotech Stock Performance

Shares of NASDAQ LEGN opened at $41.41 on Friday. Legend Biotech has a 12 month low of $39.13 and a 12 month high of $77.32. The company has a quick ratio of 5.57, a current ratio of 5.66 and a debt-to-equity ratio of 0.25. The company has a market cap of $7.55 billion, a P/E ratio of -31.85 and a beta of 0.12. The business’s 50 day moving average is $50.00 and its two-hundred day moving average is $56.99.

Legend Biotech (NASDAQ:LEGN) last announced its earnings results on Monday, May 13th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.13. The business had revenue of $93.90 million for the quarter, compared to analyst estimates of $143.24 million. Legend Biotech had a negative net margin of 135.92% and a negative return on equity of 27.91%. Legend Biotech’s revenue was up 158.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.40) earnings per share. On average, equities analysts expect that Legend Biotech will post -1.84 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. Massachusetts Financial Services Co. MA increased its holdings in Legend Biotech by 6.3% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,984,826 shares of the company’s stock valued at $119,427,000 after purchasing an additional 117,794 shares in the last quarter. TimesSquare Capital Management LLC raised its holdings in shares of Legend Biotech by 15.4% in the fourth quarter. TimesSquare Capital Management LLC now owns 1,065,889 shares of the company’s stock valued at $64,135,000 after buying an additional 142,118 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its holdings in shares of Legend Biotech by 15.9% in the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 163,130 shares of the company’s stock valued at $9,816,000 after buying an additional 22,376 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its position in Legend Biotech by 101.5% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 1,708,510 shares of the company’s stock worth $114,761,000 after buying an additional 860,410 shares in the last quarter. Finally, Westfield Capital Management Co. LP grew its holdings in Legend Biotech by 71.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 1,668,150 shares of the company’s stock worth $112,050,000 after acquiring an additional 696,096 shares during the last quarter. Institutional investors own 70.89% of the company’s stock.

Legend Biotech Company Profile

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).